Overview
- Definium reported Monday that its Emerge Phase 3 trial met the primary endpoint, showing a placebo‑adjusted 8.1‑point improvement on the MADRS depression scale at six weeks in 149 adults given a single 100 µg dose of DT120.
- Company data showed benefit as early as one week and maintained improvement through 12 weeks, with about 35% achieving a ≥50% symptom reduction at week six and 12% reaching remission versus 3% on placebo.
- Definium said DT120 was generally well tolerated, reporting that about 99% of adverse events were mild to moderate, most occurred on dosing day, and no new safety signals or rise in suicidal thoughts were observed.
- The announcement sent Definium shares sharply higher and gave analysts reason for bullish notes; the company holds roughly $411.6 million in cash, has Breakthrough Therapy designation for related indications, and plans to advance regulatory filing plans while the Ascend Phase 3 runs.
- The result advances a new class of single‑dose psychedelic therapies but key next steps include full public release of the dataset, independent review and a positive second pivotal trial before regulatory approval and broad clinical adoption can be expected.